Concepts (108)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Flavobacteriaceae | 4 | 2024 | 4 | 0.500 |
Why?
|
| Anti-Bacterial Agents | 5 | 2026 | 809 | 0.430 |
Why?
|
| Levofloxacin | 2 | 2024 | 13 | 0.390 |
Why?
|
| Fluoroquinolones | 2 | 2024 | 33 | 0.390 |
Why?
|
| Cephalosporins | 2 | 2026 | 21 | 0.370 |
Why?
|
| Microbial Sensitivity Tests | 4 | 2026 | 208 | 0.340 |
Why?
|
| Head and Neck Neoplasms | 3 | 2025 | 166 | 0.340 |
Why?
|
| Delphi Technique | 2 | 2025 | 113 | 0.260 |
Why?
|
| DNA Gyrase | 2 | 2024 | 10 | 0.260 |
Why?
|
| Ciprofloxacin | 2 | 2024 | 24 | 0.250 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 2 | 2025 | 65 | 0.250 |
Why?
|
| Acinetobacter baumannii | 1 | 2026 | 7 | 0.240 |
Why?
|
| Carbapenems | 1 | 2026 | 8 | 0.240 |
Why?
|
| Flavobacteriaceae Infections | 2 | 2024 | 2 | 0.240 |
Why?
|
| Drug Resistance, Bacterial | 2 | 2024 | 97 | 0.240 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2026 | 132 | 0.220 |
Why?
|
| Jaw Diseases | 1 | 2025 | 2 | 0.220 |
Why?
|
| Osteoradionecrosis | 1 | 2025 | 4 | 0.220 |
Why?
|
| Pneumocystis carinii | 1 | 2024 | 8 | 0.210 |
Why?
|
| Nasopharyngeal Neoplasms | 1 | 2025 | 51 | 0.210 |
Why?
|
| Pneumonia, Pneumocystis | 1 | 2024 | 19 | 0.210 |
Why?
|
| Janus Kinase Inhibitors | 1 | 2024 | 20 | 0.210 |
Why?
|
| Paranasal Sinus Neoplasms | 1 | 2024 | 6 | 0.200 |
Why?
|
| Global Health | 1 | 2025 | 181 | 0.200 |
Why?
|
| Rifampin | 1 | 2023 | 26 | 0.200 |
Why?
|
| Vancomycin | 1 | 2023 | 40 | 0.200 |
Why?
|
| Hypersensitivity | 1 | 2024 | 73 | 0.190 |
Why?
|
| Biological Products | 1 | 2024 | 93 | 0.190 |
Why?
|
| Rheumatic Fever | 1 | 2022 | 5 | 0.180 |
Why?
|
| Pharyngitis | 1 | 2022 | 14 | 0.180 |
Why?
|
| Arthritis | 1 | 2022 | 53 | 0.180 |
Why?
|
| Antirheumatic Agents | 1 | 2024 | 227 | 0.180 |
Why?
|
| Radiotherapy Dosage | 2 | 2025 | 88 | 0.180 |
Why?
|
| Myocarditis | 1 | 2022 | 68 | 0.170 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2024 | 347 | 0.160 |
Why?
|
| Dental Enamel Hypoplasia | 1 | 2020 | 2 | 0.160 |
Why?
|
| Incisor | 1 | 2020 | 7 | 0.160 |
Why?
|
| Mutation | 2 | 2024 | 2674 | 0.140 |
Why?
|
| Personnel Staffing and Scheduling | 1 | 2018 | 67 | 0.130 |
Why?
|
| Severe Dengue | 1 | 2017 | 24 | 0.130 |
Why?
|
| Proteus Infections | 1 | 2016 | 2 | 0.130 |
Why?
|
| Internal Medicine | 1 | 2018 | 154 | 0.120 |
Why?
|
| Mandible | 1 | 2016 | 8 | 0.120 |
Why?
|
| Klebsiella Infections | 1 | 2016 | 25 | 0.120 |
Why?
|
| Radiometry | 1 | 2016 | 39 | 0.120 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2016 | 37 | 0.120 |
Why?
|
| Escherichia coli Infections | 1 | 2016 | 90 | 0.120 |
Why?
|
| Community-Acquired Infections | 1 | 2016 | 95 | 0.120 |
Why?
|
| Radiation Injuries | 1 | 2016 | 67 | 0.120 |
Why?
|
| Bacteremia | 1 | 2016 | 92 | 0.120 |
Why?
|
| Neoplasms | 1 | 2025 | 1378 | 0.110 |
Why?
|
| Humans | 15 | 2026 | 65843 | 0.100 |
Why?
|
| DNA Topoisomerase IV | 2 | 2024 | 3 | 0.100 |
Why?
|
| Tumor Burden | 2 | 2025 | 77 | 0.090 |
Why?
|
| Internship and Residency | 1 | 2018 | 800 | 0.080 |
Why?
|
| Ceftazidime | 1 | 2026 | 3 | 0.060 |
Why?
|
| Azabicyclo Compounds | 1 | 2026 | 6 | 0.060 |
Why?
|
| beta-Lactamases | 1 | 2026 | 18 | 0.060 |
Why?
|
| Drug Combinations | 1 | 2026 | 167 | 0.060 |
Why?
|
| Child | 3 | 2022 | 4652 | 0.060 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 1 | 2026 | 60 | 0.060 |
Why?
|
| Gross Domestic Product | 1 | 2025 | 1 | 0.060 |
Why?
|
| Female | 6 | 2025 | 34424 | 0.050 |
Why?
|
| Electrophoresis, Gel, Pulsed-Field | 1 | 2024 | 11 | 0.050 |
Why?
|
| Consensus | 1 | 2025 | 175 | 0.050 |
Why?
|
| Health Expenditures | 1 | 2025 | 122 | 0.050 |
Why?
|
| Terminology as Topic | 1 | 2025 | 145 | 0.050 |
Why?
|
| Genes, rRNA | 1 | 2022 | 9 | 0.050 |
Why?
|
| Male | 5 | 2025 | 31410 | 0.050 |
Why?
|
| Nucleotides | 1 | 2022 | 48 | 0.050 |
Why?
|
| Fever | 1 | 2022 | 67 | 0.040 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2022 | 107 | 0.040 |
Why?
|
| Incidence | 1 | 2025 | 1433 | 0.040 |
Why?
|
| Phylogeny | 1 | 2022 | 400 | 0.040 |
Why?
|
| Sequence Analysis, DNA | 1 | 2022 | 417 | 0.040 |
Why?
|
| Cohort Studies | 2 | 2017 | 2651 | 0.040 |
Why?
|
| Molar | 1 | 2020 | 4 | 0.040 |
Why?
|
| Zebrafish | 1 | 2023 | 374 | 0.040 |
Why?
|
| Adult | 3 | 2024 | 17579 | 0.040 |
Why?
|
| Aged | 3 | 2024 | 15147 | 0.040 |
Why?
|
| Adolescent | 2 | 2022 | 6368 | 0.040 |
Why?
|
| Middle Aged | 3 | 2024 | 18501 | 0.030 |
Why?
|
| Partial Thromboplastin Time | 1 | 2017 | 9 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2025 | 2790 | 0.030 |
Why?
|
| Taiwan | 1 | 2017 | 14 | 0.030 |
Why?
|
| Aspartate Aminotransferases | 1 | 2017 | 35 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2024 | 3340 | 0.030 |
Why?
|
| Proteus mirabilis | 1 | 2016 | 2 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2020 | 1148 | 0.030 |
Why?
|
| Aged, 80 and over | 2 | 2017 | 5682 | 0.030 |
Why?
|
| Quality of Life | 1 | 2024 | 1266 | 0.030 |
Why?
|
| Propensity Score | 1 | 2016 | 192 | 0.030 |
Why?
|
| Prevalence | 1 | 2020 | 1454 | 0.030 |
Why?
|
| Ambulatory Care | 1 | 2018 | 318 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2016 | 579 | 0.030 |
Why?
|
| Inpatients | 1 | 2018 | 322 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2017 | 746 | 0.030 |
Why?
|
| Risk Factors | 1 | 2024 | 5475 | 0.030 |
Why?
|
| Diagnostic Imaging | 1 | 2016 | 274 | 0.020 |
Why?
|
| Intensive Care Units | 1 | 2017 | 437 | 0.020 |
Why?
|
| Pregnancy | 1 | 2020 | 2401 | 0.020 |
Why?
|
| Prognosis | 1 | 2017 | 1793 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2017 | 2089 | 0.020 |
Why?
|
| Hospitalization | 1 | 2017 | 1404 | 0.020 |
Why?
|
| Young Adult | 1 | 2017 | 4883 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2016 | 5834 | 0.010 |
Why?
|
| Animals | 1 | 2023 | 21492 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2016 | 6957 | 0.010 |
Why?
|